NEW NURSE - OCTOBER 2000 by qjeqk4P

VIEWS: 0 PAGES: 26

									                                                                                             Library Network




                        Alzheimer’s Disease

                                      August 08

                    Current Awareness Bulletin



Most of the following articles are available online via the NHS Scotland eLibrary.
Please use the links where provided and your ATHENS password. A complete list of
available online journals and registration for ATHENS can be found at
http://www.elib.scot.nhs.uk/


If you would like to request print copies of any of the articles please contact your
nearest library or visit the library website for further details.

                        http://www.nhsggc.org.uk/libraryservices

  Please note inter-library requests will only be done for South Glasgow NHS staff.
Please note, the articles you are accessing may be protected by copyright legislation, please
contact your librarian for a copyright declaration form if you are in any doubt. Or, consult the
Copyright Licensing Agency at http://www.cla.co.uk


If you have any questions regarding this or any other library services please contact
your librarian.

Compiled by C. Boulnois
Library Services Manager (South)
NHS Greater Glasgow & Clyde Library Network
Central Library
Southern General Hospital
1345 Govan Rd
G51 4TF
0141 201 2163
charlotte.boulnois@sgh.scot.nhs.uk

 Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
                           current articles and not intended to be exhaustive.
                                             References

1.   Adachi M, Kawanami T, Kawakatsu S, Shibata A, Ohshima F. Rounding of the

     hippocampus in alzheimer's disease: A study by routine coronal magnetic resonance

     imaging. Radiation Medicine - Medical Imaging and Radiation Oncology. 2007;

     25(5):224-228.


2.   Agarwal S, Tannenberg RK, Dodd PR. Reduced expression of the inhibitory synapse

     scaffolding protein gephyrin in alzheimer's disease. J Alzheimer's Dis. 2008;

     14(3):313-321.


3.   Akram A, Christoffel D, Rocher AB, et al. Stereologic estimates of total spinophilin-

     immunoreactive spine number in area 9 and the CA1 field: Relationship with the

     progression of alzheimer's disease. Neurobiol Aging. 2008; 29(9):1296-1307.


4.   Alberghina L, Colangelo AM. The modular systems biology approach to investigate

     the control of apoptosis in alzheimer's disease neurodegeneration. BMC Neuroscience.

     2006; 7(SUPPL. 1):Arte Number: S2. ate of Pubaton: 30 Ot 2006.


5.   Aliev G, Gasimov E, Obrenovich ME, et al. Atherosclerotic lesions and mitochondria

     DNA deletions in brain microvessels: Implication in the pathogenesis of alzheimer's

     disease. Vascular Health and Risk Management. 2008; 4(3):721-730.


6.   Allain P, Le Gall D, Foucher C, et al. Script representation in patients with alzheimer's

     disease. Cortex. 2008; 44(3):294-304.


7.   Altmann LJ, McClung JS. Effects of semantic impairment on language use in

     alzheimer's disease. Seminars in Speech & Language. 2008; 29(1):18-31.


8.   Alvarez V, Corao AI, Alonso-Montes C, et al. Mitochondrial transcription factor A

     (TFAM) gene variation and risk of late-onset alzheimer's disease. J Alzheimer's Dis.

     2008; 13(3):275-280.


9.   Anderson KN, Jamieson S, Graham AJ, Shneerson JM. REM sleep behaviour disorder

     treated with melatonin in a patient with alzheimer's disease. Clinical Neurology &

     Neurosurgery. 2008; 110(5):492-495.

 Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
                           current articles and not intended to be exhaustive.
10.    Arias-Vasquez A, Aulchenko YS, Isaacs A, et al. Cyclin-dependent kinase 5 is

      associated with risk for alzheimer's disease in a dutch population-based study. J

      Neurol. 2008; 255(5):655-662.


11.    Ariga T, McDonald MP, Yu RK. Role of ganglioside metabolism in the pathogenesis of

      alzheimer's disease--a review. J Lipid Res. 2008; 49(6):1157-1175.


12.    Azevedo D, Tatsch M, Hototian SR, Bazzarella MC, Castro CC, Bottino CMC. Proton

      spectroscopy in alzheimer's disease and cognitive impairment no dementia: A

      community-based study. Dement Geriatr Cogn Disord. 2008; 25(6):491-500.


13.    Balin BJ, Little CS, Hammond CJ, et al. Chlamydophila pneumoniae and the etiology

      of late-onset alzheimer's disease. J Alzheimer's Dis. 2008; 13(4):371-380.


14.    Ballard C, Lana MM, Theodoulou M, et al. A randomised, blinded, placebo-controlled

      trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial).

      PLoS Medicine / Public Library of Science. 2008; 5(4):e76.


15.    Banks S, Weintraub S. Self-awareness and self-monitoring of cognitive and

      behavioral deficits in behavioral variant frontotemporal dementia, primary progressive

      aphasia and probable alzheimer's disease. Brain & Cognition. 2008; 67(1):58-68.


16.    Barnes J, Scahill RI, Frost C, Schott JM, Rossor MN, Fox NC. Increased hippocampal

      atrophy rates in AD over 6 months using serial MR imaging. Neurobiol Aging. 2008;

      29(8):1199-1203.


17.    Bateman RJ, Klunk WE. Measuring target effect of proposed disease-modifying

      therapies in alzheimer's disease. Neurotherapeutics. 2008; 5(3):381-390.


18.    Bekris LM, Millard SP, Galloway NM, et al. Multiple SNPs within and surrounding the

      apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels. J

      Alzheimer's Dis. 2008; 13(3):255-266.




 Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
                           current articles and not intended to be exhaustive.
19.    Belbin O, Dunn JL, Chappell S, et al. A SNP in the ACT gene associated with

      astrocytosis and rapid cognitive decline in AD. Neurobiol Aging. 2008; 29(8):1167-

      1176.


20.    Bermejo P, Martin-Aragon S, Benedi J, et al. Differences of peripheral inflammatory

      markers between mild cognitive impairment and alzheimer's disease. Immunol Lett.

      2008; 117(2):198-202.


21.    Bier N, Van Der Linden M, Gagnon L, et al. Face-name association learning in early

      alzheimer's disease: A comparison of learning methods and their underlying

      mechanisms. Neuropsychological Rehabilitation. 2008; 18(3):343-371.


22.    Bigio EH. TAR DNA-binding protein-43 in amyotrophic lateral sclerosis,

      frontotemporal lobar degeneration, and alzheimer disease. Acta Neuropathol. 2008;

      116(2):135-140.


23.    Boldogh I, Kruzel ML. Colostrinin: An oxidative stress modulator for prevention and

      treatment of age-related disorders. J Alzheimer's Dis. 2008; 13(3):303-321.


24.    Borthakur A, Sochor M, Davatzikos C, Trojanowski JQ, Clark CM. T1rho MRI of

      alzheimer's disease. Neuroimage. 2008; 41(4):1199-1205.


25.    Bruandet A, Richard F, Tzourio C, et al. Haplotypes across ACE and the risk of

      alzheimer's disease: The three-city study. J Alzheimer's Dis. 2008; 13(3):333-339.


26.    Bryan K, Lee H-, Perry G, Castellani RJ, Smith MA, Casadesus G. Nonestrogen-

      based hormonal therapies for alzheimer's disease. Future Neurology. 2008; 3(4):399-

      407.


27.    Buchhave P, Stomrud E, Warkentin S, Blennow K, Minthon L, Hansson O. Cube

      copying test in combination with rCBF or CSF Abeta42 predicts development of

      alzheimer's disease. Dement Geriatr Cogn Disord. 2008; 25(6):544-552.




 Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
                           current articles and not intended to be exhaustive.
28.    Bullido MJ, Martinez-Garcia A, Tenorio R, et al. Double stranded RNA activated EIF2

      alpha kinase (EIF2AK2; PKR) is associated with alzheimer's disease. Neurobiol Aging.

      2008; 29(8):1160-1166.


29.    Burgener SC, Berger B. Measuring perceived stigma in persons with progressive

      neurological disease: Alzheimer's dementia and parkinson's disease. Dementia. 2008;

      7(1):31-53.


30.    Burns JM, Cronk BB, Anderson HS, et al. Cardiorespiratory fitness and brain atrophy

      in early alzheimer disease. Neurology. 2008; 71(3):210-216.


31.    Bush AI, Tanzi RE. Therapeutics for alzheimer's disease based on the metal

      hypothesis. Neurotherapeutics. 2008; 5(3):421-432.


32.    Capps D. Alzheimer's disease and the loss of self. The Journal of Pastoral Care &

      Counseling: JPCC. 2008; 62(1-2):19-28.


33.    Carney RM, Slifer MA, Lin PI, et al. Longitudinal follow-up of late-onset alzheimer

      disease families. American Journal of Medical Genetics, Part B: Neuropsychiatric

      Genetics. 2008; 147(5):571-578.


34.    Cerpa W, Dinamarca MC, Inestrosa NC. Structure-function implications in

      alzheimer's disease: Effect of abeta oligomers at central synapses. Current Alzheimer

      Research. 2008; 5(3):233-243.


35.    Chen Z, Simmons MS, Perry RT, Wiener HW, Harrell LE, Go RC. Genetic association

      of neurotrophic tyrosine kinase receptor type 2 (NTRK2) with alzheimer's disease.

      American Journal of Medical Genetics.Part B, Neuropsychiatric Genetics: the Official

      Publication of the International Society of Psychiatric Genetics. 2008; 147(3):363-

      369.


36.    Christensen KD, Roberts JS, Royal CD, et al. Incorporating ethnicity into genetic risk

      assessment for alzheimer disease: The REVEAL study experience. Genetics in

      Medicine. 2008; 10(3):207-214.




 Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
                           current articles and not intended to be exhaustive.
37.    Colliot O, Chetelat G, Chupin M, et al. Discrimination between alzheimer disease,

      mild cognitive impairment, and normal aging by using automated segmentation of the

      hippocampus. Radiology. 2008; 248(1):194-201.


38.    Connelly PJ, Prentice NP, Cousland G, Bonham J. A randomised double-blind

      placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in

      alzheimer's disease. Int J Geriatr Psychiatry. 2008; 23(2):155-160.


39.    Cooper C, Owens C, Katona C, Livingston G. Attachment style and anxiety in carers

      of people with alzheimer's disease: Results from the LASER-AD study. International

      Psychogeriatrics. 2008; 20(3):494-507.


40.    Corder EH, Blennow K, Prince JA. Genetic susceptibility sets for alzheimer's disease

      identified from diverse candidate loci. Rejuvenation Research. 2008; 11(3):667-679.


41.    Counts SE, Perez SE, Mufson EJ. Galanin in alzheimer's disease: Neuroinhibitory or

      neuroprotective? Cellular & Molecular Life Sciences. 2008; 65(12):1842-1853.


42.    Creese J, Bedard M, Brazil K, Chambers L. Sleep disturbances in spousal caregivers

      of individuals with alzheimer's disease. Int Psychogeriatr. 2008; 20(1):149-161.


43.    De Anna F, Attali E, Freynet L, et al. Intrusions in story recall: When over-learned

      information interferes with episodic memory recall. evidence from alzheimer's

      disease. Cortex. 2008; 44(3):305-311.


44.    De Felice FG, Wu D, Lambert MP, et al. Alzheimer's disease-type neuronal tau

      hyperphosphorylation induced by abeta oligomers. Neurobiol Aging. 2008;

      29(9):1334-1347.


45.    de Jong D, Jansen R, Hoefnagels W, et al. No effect of one-year treatment with

      indomethacin on alzheimer's disease progression: A randomized controlled trial. PLoS

      ONE [Electronic Resource]. 2008; 3(1):e1475.


46.    De La Torre JC. Alzheimer's disease prevalence can be lowered with non-invasive

      testing. J Alzheimer's Dis. 2008; 14(3):353-359.



 Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
                           current articles and not intended to be exhaustive.
47.    de Oliveira RM, Lia EN, Guimaraes RM, Bocca AL, Cavalcante Neto FF, da Silva TA.

      Cytologic and cytometric analysis of oral mucosa in alzheimer's disease. Analytical &

      Quantitative Cytology & Histology. 2008; 30(2):113-118.


48.    Dearie R, Sagare A, Zlokovic BV. The role of the cell surface LRP and soluble LRP in

      blood-brain barrier abeta clearance in alzheimer's disease. Curr Pharm Des. 2008;

      14(16):1601-1605.


49.    Del Tredici K, Braak H. Neurofibrillary changes of the alzheimer type in very elderly

      individuals: Neither inevitable nor benign. commentary on "no disease in the brain of

      a 115-year-old woman". Neurobiol Aging. 2008; 29(8):1133-1136.


50.    Dickerson BC. Pre-dementia diagnosis of alzheimer's disease: Translating

      clinicobiologic research into practice. Current Psychiatry Reviews. 2008; 4(2):73-79.


51.    Diniz BSO, Pinto J, J.a, Forlenza OV. Do CSF total tau, phosphorylated tau, and b-

      amyloid 42 help to predict progression of mild cognitive impairment to alzheimer's

      disease? A systematic review and meta-analysis of the literature. World Journal of

      Biological Psychiatry. 2008; 9(3):172-182.


52.    Erol A. An integrated and unifying hypothesis for the metabolic basis of sporadic

      alzheimer's disease. J Alzheimer's Dis. 2008; 13(3):241-253.


53.    Faghihi MA, Modarresi F, Khalil AM, et al. Expression of a noncoding RNA is elevated

      in alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat

      Med. 2008; 14(7):723-730.


54.    Farlow MR, Graham SM, Alva G. Memantine for the treatment of alzheimer's

      disease: Tolerability and safety data from clinical trials. Drug Safety. 2008;

      31(7):577-585.


55.    Farran CJ, Staffileno BA, Gilley DW, et al. A lifestyle physical activity intervention for

      caregivers of persons with alzheimer's disease. American Journal of Alzheimer's

      Disease & Other Dementias. 2008; 23(2):132-142.




 Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
                           current articles and not intended to be exhaustive.
56.    Fischer P, Zehetmayer S, Jungwirth S, et al. Risk factors for alzheimer dementia in a

      community-based birth cohort at the age of 75 years. Dement Geriatr Cogn Disord.

      2008; 25(6):501-507.


57.    Fisher A. Cholinergic treatments with emphasis on M1 muscarinic agonists as

      potential disease-modifying agents for alzheimer's disease. Neurotherapeutics. 2008;

      5(3):433-442.


58.    Flieisher AS, Raman R, Siemers ER, et al. Phase 2 safety trial targetintg amyloid B

      production with a y-secretase inhibitor in alzheimer disease. Archives of Neurology.

      2008; 65(8):1031-1038.


59.    Florean C, Zampese E, Zanese M, et al. High content analysis of gamma-secretase

      activity reveals variable dominance of presenilin mutations linked to familial

      alzheimer's disease. Biochimica et Biophysica Acta - Molecular Cell Research. 2008;

      1783(8):1551-1560.


60.    Fottrell E. Preventing or delaying the effects of alzheimer's disease. Geriatr Med.

      2008; 38(5):283, 285-6.


61.    Foulds P, McAuley E, Gibbons L, et al. TDP-43 protein in plasma may index TDP-43

      brain pathology in alzheimer's disease and frontotemporal lobar degeneration. Acta

      Neuropathol. 2008; 116(2):141-146.


62.    Freund-Levi Y, Basun H, Cederholm T, et al. Omega-3 supplementation in mild to

      moderate alzheimer's disease: Effects on neuropsychiatric symptoms. Int J Geriatr

      Psychiatry. 2008; 23(2):161-169.


63.    Fujishiro H, Tsuboi Y, Lin W-, Uchikado H, Dickson DW. Co-localization of tau and

      alpha-synuclein in the olfactory bulb in alzheimer's disease with amygdala lewy

      bodies. Acta Neuropathol. 2008; 116(1):17-24.


64.    Galimberti D, Scarpini E, Venturelli E, et al. Association of a NOS1 promoter repeat

      with alzheimer's disease. Neurobiol Aging. 2008; 29(9):1359-1365.




 Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
                           current articles and not intended to be exhaustive.
65.    Galimberti G, Conti E, Zini M, et al. Post-methionine load test: A more sensitive tool

      to reveal hyperhomocysteinemia in alzheimer patients?. Clin Biochem. 2008; 41(10-

      11):914-916.


66.    Gates GA, Anderson ML, Feeney MP, McCurry SM, Larson EB. Central auditory

      dysfunction in older persons with memory impairment or alzheimer dementia.

      Archives of Otolaryngology -- Head & Neck Surgery. 2008; 134(7):771-777.


67.    Geldmacher DS. Cost-effectiveness of drug therapies for alzheimer's disease: A brief

      review. Neuropsychiatric Disease and Treatment. 2008; 4(3):549-555.


68.    Gerhardsson L, Lundh T, Minthon L, Londos E. Metal concentrations in plasma and

      cerebrospinal fluid in patients with alzheimer's disease. Dement Geriatr Cogn Disord.

      2008; 25(6):508-515.


69.    Germano C, Kinsella GJ, Storey E, Ong B, Ames D. The episodic buffer and learning

      in early alzheimer's disease. Journal of Clinical and Experimental Neuropsychology.

      2008; 30(6):627-638.


70.    Ghosh AK, Gemma S, Tang J. Beta-secretase as a therapeutic target for alzheimer's

      disease. Neurotherapeutics. 2008; 5(3):399-408.


71.    Giannakopoulos P, Bouras C, Hof PR. Clinicopathologic correlates in the oldest-old.

      commentary on "no disease in the brain of a 115-year-old woman". Neurobiol Aging.

      2008; 29(8):1137-1139.


72.    Giovagnoli AR, Erbetta A, Reati F, Bugiani O. Differential neuropsychological

      patterns of frontal variant frontotemporal dementia and alzheimer's disease in a study

      of diagnostic concordance. Neuropsychologia. 2008; 46(5):1495-1504.


73.    Gomez JM. Growth hormone and insulin-like growth factor-I as an endocrine axis in

      alzheimer's disease. Endocrine, Metabolic & Immune Disorders Drug Targets. 2008;

      8(2):143-151.




 Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
                           current articles and not intended to be exhaustive.
74.    Greilberger J, Koidl C, Greilberger M, et al. Malondialdehyde, carbonyl proteins and

      albumin-disulphide as useful oxidative markers in mild cognitive impairment and

      alzheimer's disease. Free Radic Res. 2008; 42(7):633-638.


75.    Hagnelius N-, Wahlund L-, Nilsson TK. CSF/serum folate gradient: Physiology and

      determinants with special reference to dementia. Dement Geriatr Cogn Disord. 2008;

      25(6):516-523.


76.    Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and

      safety of donepezil, galantamine, and rivastigmine for the treatment of alzheimer's

      disease: A systematic review and meta-analysis. Clinical Interventions in Aging.

      2008; 3(2):211-225.


77.    Haque A, Banik NL, Ray SK. New insights into the roles of endolysosomal cathepsins

      in the pathogenesis of alzheimer's disease: Cathepsin inhibitors as potential

      therapeutics. CNS and Neurological Disorders - Drug Targets. 2008; 7(3):270-277.


78.    Harnish SM, Neils-Strunjas J. In search of meaning: Reading and writing in

      alzheimer's disease. Seminars in Speech & Language. 2008; 29(1):44-59.


79.    Hashioka S, Miklossy J, Schwab C, Klegeris A, McGeer PL. Adhesion of exogenous

      human microglia and THP-1 cells to amyloid plaques of postmortem alzheimer's

      disease brain. J Alzheimer's Dis. 2008; 14(3):345-352.


80.    Hawley KS, Cherry KE, Boudreaux EO, Jackson EM. A comparison of adjusted

      spaced retrieval versus a uniform expanded retrieval schedule for learning a name-

      face association in older adults with probable alzheimer's disease. Journal of Clinical

      and Experimental Neuropsychology. 2008; 30(6):639-649.


81.    Hawranik P, Johnston P, Deatrich J. Therapeutic touch and agitation in individuals

      with alzheimer's disease. West J Nurs Res. 2008; 30(4):417-434.


82.    Helisalmi S, Vepsalainen S, Hiltunen M, et al. Genetic study between SIRT1, PPARD,

      PGC-1alpha genes and alzheimer's disease. J Neurol. 2008; 255(5):668-673.




 Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
                           current articles and not intended to be exhaustive.
83.    Henderson ST. Ketone bodies as a therapeutic for alzheimer's disease.

      Neurotherapeutics. 2008; 5(3):470-480.


84.    Henry JD, Ruffman T, McDonald S, et al. Recognition of disgust is selectively

      preserved in alzheimer's disease. Neuropsychologia. 2008; 46(5):1363-1370.


85.    Hoozemans JJM, Rozemuller JM, van Haastert ES, Veerhuis R, Eikelenboom P.

      Cyclooxygenase-1 and -2 in the different stages of alzheimer's disease pathology.

      Curr Pharm Des. 2008; 14(14):1419-1427.


86.    House MJ, St, Pierre TG, McLean C. 1.4T study of proton magnetic relaxation rates,

      iron concentrations, and plaque burden in alzheimer's disease and control

      postmortem brain tissue. Magnetic Resonance in Medicine. 2008; 60(1):41-52.


87.    Hsiung G-R, Alipour S, Jacova C, et al. Transition from cognitively impaired not

      demented to alzheimer's disease: An analysis of changes in functional abilities in a

      dementia clinic cohort. Dement Geriatr Cogn Disord. 2008; 25(6):483-490.


88.    Hu WT, Josephs KA, Knopman DS, et al. Temporal lobar predominance of TDP-43

      neuronal cytoplasmic inclusions in alzheimer disease. Acta Neuropathol. 2008;

      116(2):215-220.


89.    Hudson JM. Automatic memory processes in normal ageing and alzheimer's disease.

      Cortex. 2008; 44(3):345-349.


90.    Im K, Lee JM, Seo SW, et al. Variations in cortical thickness with dementia severity

      in alzheimer's disease. Neurosci Lett. 2008; 436(2):227-231.


91.    Irizarry MC, Webb DJ, Bains C, et al. Predictors of placebo group decline in the

      alzheimer's disease assessment scale-cognitive subscale (ADAS-cog) in 24 week

      clinical trials of alzheimer's disease. J Alzheimer's Dis. 2008; 14(3):301-311.


92.    Ismail Z, Herrmann N, Rothenburg LS, et al. A functional neuroimaging study of

      appetite loss in alzheimer's disease. J Neurol Sci. 2008; 271(1-2):97-103.




 Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
                           current articles and not intended to be exhaustive.
93.     Itzhaki RF, Wozniak MA. Herpes simplex virus type 1 in alzheimer's disease: The

       enemy within. J Alzheimer's Dis. 2008; 13(4):393-405.


94.     Jayaratnam S, Khoo AK, Basic D. Rapidly progressive alzheimer's disease and

       elevated 14-3-3 proteins in cerebrospinal fluid. Age & Ageing. 2008; 37(4):467-469.


95.     Jenkins EC, Ye L, Gu H, et al. Increased "absence" of telomeres may indicate

       alzheimer's disease/dementia status in older individuals with down syndrome.

       Neurosci Lett. 2008; 440(3):340-343.


96.     Juckel G, Clotz F, Frodl T, et al. Diagnostic usefulness of cognitive auditory event-

       related p300 subcomponents in patients with alzheimers disease?. Journal of Clinical

       Neurophysiology. 2008; 25(3):147-152.


97.     Jung SM, Lee K, Lee JW, et al. Both plasma retinol-binding protein and haptoglobin

       precursor allele 1 in CSF: Candidate biomarkers for the progression of normal to mild

       cognitive impairment to alzheimer's disease. Neurosci Lett. 2008; 436(2):153-157.


98.     Kadir A, Darreh-Shori T, Almkvist O, et al. PET imaging of the in vivo brain

       acetylcholinesterase activity and nicotine binding in galantamine-treated patients with

       AD. Neurobiol Aging. 2008; 29(8):1204-1217.


99.     Kalaria RN, Maestre GE, Arizaga R, et al. Alzheimer's disease and vascular dementia

       in developing countries: Prevalence, management and risk factors. Lancet Neurology.

       2008; 7(9):812-826.


100.      Kamal MA, Qu X, Yu Q-, et al. Tetrahydrofurobenzofuran cymserine, a potent

       butyrylcholinesterase inhibitor and experimental alzheimer drug candidate, enzyme

       kinetic analysis. J Neural Transm. 2008; 115(6):889-898.


101.      Kamer AR, Dasanayake AP, Craig RG, Glodzik-Sobanska L, Bry M, de Leon MJ.

       Alzheimer's disease and peripheral infections: The possible contribution from

       periodontal infections, model and hypothesis. J Alzheimer's Dis. 2008; 13(4):437-

       449.




 Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
                           current articles and not intended to be exhaustive.
102.     Kanetaka H, Hanyu H, Hirao K, et al. Prediction of response to donepezil in

       alzheimer's disease: Combined MRI analysis of the substantia innominata and SPECT

       measurement of cerebral perfusion. Nucl Med Commun. 2008; 29(6):568-573.


103.     Kantarci K, Knopman DS, Dickson DW, et al. Alzheimer disease: Postmortem

       neuropathologic correlates of antemortem 1H MR spectroscopy metabolite

       measurements. Radiology. 2008; 248(1):210-220.


104.     Kawarabayashi T, Shoji M. Plasma biomarkers of alzheimer's disease. Current

       Opinion in Psychiatry. 2008; 21(3):260-267.


105.     Kharrazi H, Vaisi-Raygani A, Rahimi Z, Tavilani H, Aminian M, Pourmotabbed T.

       Association between enzymatic and non-enzymatic antioxidant defense mechanism

       with apolipoprotein E genotypes in alzheimer disease. Clin Biochem. 2008;

       41(12):932-936.


106.     Kidd PM. Alzheimer's disease, amnestic mild cognitive impairment, and age-

       associated memory impairment: Current understanding and progress toward

       integrative prevention. Alternative Medicine Review. 2008; 13(2):85-115.


107.     Kim TS, Lim HK, Lee JY, et al. Changes in the levels of plasma soluble fractalkine

       in patients with mild cognitive impairment and alzheimer's disease. Neurosci Lett.

       2008; 436(2):196-200.


108.     Klepping L. Sexuality for people with learning disabilities and alzheimer's disease:

       The ex-PLISSIT model. Learn Disabil Pract. 2008; 11(4):28-32.


109.     Kluger A, Gianutsos JG, Golomb J, Wagner AJ, Wagner D, Scheurich S. Clinical

       features of MCI: Motor changes. Int Psychogeriatr. 2008; 20(1):32-39.


110.     Kolsch H, Jessen F, Wiltfang J, et al. Influence of SORL1 gene variants: Association

       with CSF amyloid-beta products in probable alzheimer's disease. Neurosci Lett. 2008;

       440(1):68-71.




Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
                          current articles and not intended to be exhaustive.
111.      Krone MG, Baumketner A, Bernstein SL, et al. Effects of familial alzheimer's

       disease mutations on the folding nucleation of the amyloid beta-protein. J Mol Biol.

       2008; 381(1):221-228.


112.      Landreth G, Jiang Q, Mandrekar S, Heneka M. PPARgamma agonists as

       therapeutics for the treatment of alzheimer's disease. Neurotherapeutics. 2008;

       5(3):481-489.


113.      Lannfelt L, Blennow K, Zetterberg H, et al. Safety, efficacy and biomarker findings

       of PBT2 in targeting AB as a modifying therapy for alzheimer's disease: A phase 11a

       double-blind , randomised, placebo-controlled trial. Lancet Neurology. 2008;

       7(9):779-786.


114.      Lanni C, Racchi M, Mazzini G, et al. Conformationally altered p53: A novel

       alzheimer's disease marker?. Mol Psychiatry. 2008; 13(6):641-647.


115.      Lukiw WJ. Emerging amyloid beta (ab) peptide modulators for the treatment of

       alzheimer's disease (AD). Expert Opinion on Emerging Drugs. 2008; 13(2):255-271.


116.      Lukiw WJ. Emerging amyloid beta (abeta) peptide modulators for the treatment of

       alzheimer's disease (AD). Expert Opinion on Emerging Drugs. 2008; 13(2):255-271.


117.      Macdonald A, Briggs K, Poppe M, Higgins A, Velayudhan L, Lovestone S. A

       feasibility and tolerability study of lithium in alzheimer's disease. Int J Geriatr

       Psychiatry. 2008; 23(7):704-711.


118.      Maczurek A, Shanmugam K, Munch G. Inflammation and the redox-sensitive AGE-

       RAGE pathway as a therapeutic target in alzheimer's disease. Ann N Y Acad Sci.

       2008; 1126:147-151.


119.      Mahon MM, Sorrell JM. Palliative care for people with alzheimer's disease. Nurs

       Philos. 2008; 9(2):110-120.




Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
                          current articles and not intended to be exhaustive.
120.      Maylor EA, Sheehan B, Watson DG, Henderson EL. Enumeration in alzheimer's

       disease and other late life psychiatric syndromes. Neuropsychologia. 2008;

       46(11):2696-2708.


121.      Meguro M, Kasai M, Akanuma K, Ishii H, Yamaguchi S, Meguro K. Comprehensive

       approach of donepezil and psychosocial interventions on cognitive function and quality

       of life for alzheimer's disease: The osaki-tajiri project. Age & Ageing. 2008;

       37(4):469-473.


122.      Melquiond A, Dong X, Mousseau N, Derreumaux P. Role of the region 23-28 in

       abeta fibril formation: Insights from simulations of the monomers and dimers of

       alzheimer's peptides Abeta40 and Abeta42. Current Alzheimer Research. 2008;

       5(3):244-250.


123.      Miklossy J. Chronic inflammation and amyloidogenesis in alzheimer's disease --

       role of spirochetes. J Alzheimer's Dis. 2008; 13(4):381-391.


124.      Moran EK, Becker JA, Satlin A, Lyoo IK, Fischman AJ, Johnson KA. Psychosis of

       alzheimer's disease: Gender differences in regional perfusion. Neurobiol Aging. 2008;

       29(8):1218-1225.


125.      Moretti R, Torre P, Antonello RM, Cazzato G, Pizzolato G. Different responses to

       rivastigmine in subcortical vascular dementia and multi-infarct dementia. American

       Journal of Alzheimer's Disease & Other Dementias. 2008; 23(2):167-176.


126.      Mucha L, Wang SS, Cuffel B, McRae T, Mark TL, del Valle M. Comparison of

       cholinesterase inhibitor utilization patterns and associated health care costs in

       alzheimer's disease. Journal of Managed Care Pharmacy. 2008; 14(5):451-461.


127.      Muntane G, Dalfo E, Martinez A, Ferrer I. Phosphorylation of tau and alpha-

       synuclein in synaptic-enriched fractions of the frontal cortex in alzheimer's disease,

       and in parkinson's disease and related alpha-synucleinopathies. Neuroscience. 2008;

       152(4):913-923.




Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
                          current articles and not intended to be exhaustive.
128.      Negri MA, Pinilla J, Leon CJ. Willingness to pay for alternative policies for patients

       with alzheimer's disease. Health Economics, Policy and Law. 2008; 3(3):257-275.


129.      Nihashi T, Yatsuya H, Hayasaka K, et al. Direct comparison study between FDG-

       PET and IMP-SPECT for diagnosing alzheimer's disease using 3D-SSP analysis in the

       same patients. Radiation Medicine - Medical Imaging and Radiation Oncology. 2007;

       25(6):255-262.


130.      Nourhashemi F, Gillette-Guyonnet S, Andrieu S, et al. A randomized trial of the

       impact of a specific care plan in 1120 alzheimer's patients (PLASA study) over a two-

       year period: Design and baseline data. J Nutr Health Aging. 2008; 12(4):263-271.


131.      Ohman A, Josephsson S, Nygard L. Awareness through interaction in everyday

       occupations: Experiences of people with alzheimer's disease. Scand J Occup Ther.

       2008; 15(1):43-51.


132.      Ortiz GG, Pacheco-Moises F, El Hafidi M, et al. Detection of membrane fluidity in

       submitochondrial particles of platelets and erythrocyte membranes from mexican

       patients with alzheimer disease by intramolecular excimer formation of 1,3

       dipyrenylpropane. Dis Markers. 2008; 24(3):151-156.


133.      Oudshoorn C, Mattace-Raso FUS, Van Der Velde N, Colin EM, Van Der Cammen

       TJM. Higher serum vitamin D3 levels are associated with better cognitive test

       performance in patients with alzheimer's disease. Dement Geriatr Cogn Disord. 2008;

       25(6):539-543.


134.      Panagopoulos PK, Tsartsalis S, Dokos C, Mironidou-Tzouveleki M. New kids on the

       block: Statins in the fight against alzheimer's disease. Review of Clinical

       Pharmacology and Pharmacokinetics, International Edition. 2008; 22(2):269-272.


135.      Pihlajamaki M, DePeau KM, Blacker D, Sperling RA. Impaired medial temporal

       repetition suppression is related to failure of parietal deactivation in alzheimer

       disease. American Journal of Geriatric Psychiatry. 2008; 16(4):283-292.




Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
                          current articles and not intended to be exhaustive.
136.      Pihlajamaki M, Sperling RA. fMRI: Use in early alzheimer's disease and in clinical

       trials. Future Neurology. 2008; 3(4):409-421.


137.      Pinhel MAS, Nakazone MA, Cacao JC, et al. Glutathione S-transferase variants

       increase susceptibility for late-onset alzheimer's disease: Association study and

       relationship with apolipoprotein E epsilon4 allele. Clinical Chemistry and Laboratory

       Medicine. 2008; 46(4):439-445.


138.      Poza J, Hornero R, Abasolo D, Fernandez A, Mayo A. Evaluation of spectral ratio

       measures from spontaneous MEG recordings in patients with alzheimer's disease.

       Computer Methods & Programs in Biomedicine. 2008; 90(2):137-147.


139.      Price JL. What does it take to stay healthy past 100?. commentary on "no disease

       in the brain of a 115-year-old woman". Neurobiol Aging. 2008; 29(8):1140-1142.


140.      Purandare N. Role of cerebral microemboli in the causation of alzheimer's disease

       and vascular dementia. Future Neurology. 2008; 3(4):391-397.


141.      Rahimi F, Shanmugam A, Bitan G. Structure-function relationships of pre-fibrillar

       protein assemblies in alzheimer's disease and related disorders. Current Alzheimer

       Research. 2008; 5(3):319-341.


142.      Ramalho RM, Viana RJ, Low WC, Steer CJ, Rodrigues CM. Bile acids and apoptosis

       modulation: An emerging role in experimental alzheimer's disease. Trends Mol Med.

       2008; 14(2):54-62.


143.      Ranginwala NA, Hynan LS, Weiner MF, White CL,3rd. Clinical criteria for the

       diagnosis of alzheimer disease: Still good after all these years. American Journal of

       Geriatric Psychiatry. 2008; 16(5):384-388.


144.      Reddy PH, Beal MF. Amyloid beta, mitochondrial dysfunction and synaptic damage:

       Implications for cognitive decline in aging and alzheimer's disease. Trends Mol Med.

       2008; 14(2):45-53.




Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
                          current articles and not intended to be exhaustive.
145.      Reekum R. Donepezil was no better than placebo for agitation in patients with

       alzheimer disease. ACP J Club. 2008; 148(2):33.


146.      Reger MA, Watson GS, Green PS, et al. Intranasal insulin administration dose-

       dependently modulates verbal memory and plasma amyloid-beta in memory-impaired

       older adults. J Alzheimer's Dis. 2008; 13(3):323-331.


147.      Reger MA, Watson GS, Green PS, et al. Intranasal insulin administration dose-

       dependently modulates verbal memory and plasma amyloid-beta in memory-impaired

       older adults. J Alzheimer's Dis. 2008; 13(3):323-331.


148.      Reisberg B, Ferris SH, Kluger A, Franssen E, Wegiel J, de Leon MJ. Mild cognitive

       impairment (MCI): A historical perspective. Int Psychogeriatr. 2008; 20(1):18-31.


149.      Ringman JM, Younkin SG, Pratico D, et al. Biochemical markers in persons with

       preclinical familial alzheimer disease. Neurology. 2008; 71(2):85-92.


150.      Rockwood K, Dai D, Mitnitski A. Patterns of decline and evidence of subgroups in

       patients with alzheimer's disease taking galantamine for up to 48 months. Int J

       Geriatr Psychiatry. 2008; 23(2):207-214.


151.      Rodriguez-Rodriguez E, Llorca J, Mateo I, et al. Brief research communication: No

       association of genetic variants of liver X receptor-beta with alzheimer's disease risk.

       American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics. 2008;

       147(5):650-653.


152.      Roepke SK, Mausbach BT, Aschbacher K, et al. Personal mastery is associated with

       reduced sympathetic arousal in stressed alzheimer caregivers. American Journal of

       Geriatric Psychiatry. 2008; 16(4):310-317.


153.      Ryan J, Scali J, Carriere I, Ritchie K, Ancelin M. Hormonal treatment, mild cognitive

       impairment and alzheimer's disease. Int Psychogeriatr. 2008; 20(1):47-56.




Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
                          current articles and not intended to be exhaustive.
154.      Sabayan B, Foroughinia F, Mowla A, Borhanihaghighi A. Role of insulin metabolism

       disturbances in the development of alzheimer disease: Mini review. American Journal

       of Alzheimer's Disease & Other Dementias. 2008; 23(2):192-199.


155.      Saddichha S, Pandey V. Alzheimer's and non-alzheimer's dementia: A critical

       review of pharmacological and nonpharmacological strategies. American Journal of

       Alzheimer's Disease & Other Dementias. 2008; 23(2):150-161.


156.      Salloway S, Correia S, Richardson S. Key lessons learned from short-term

       treatment trials of cholinesterase inhibitors for amnestic MCI. Int Psychogeriatr.

       2008; 20(1):40-46.


157.      Scacchi R, Gambina G, Broggio E, Ruggeri M, Corbo RM. C-338A polymorphism of

       the endothelin-converting enzyme (ECE-1) gene and the susceptibility to sporadic

       late-onset alzheimer's disease and coronary artery disease. Dis Markers. 2008;

       24(3):175-179.


158.      Schmidtke K, Hermeneit S. High rate of conversion to alzheimer's disease in a

       cohort of amnestic MCI patients. Int Psychogeriatr. 2008; 20(1):96-108.


159.      Schultz SK. Atypical antipsychotic medications in alzheimer's disease:

       Effectiveness versus expectations. Am J Psychiatry. 2008; 165(7):787-789.


160.      Schwab C, McGeer PL. Inflammatory aspects of alzheimer disease and other

       neurodegenerative disorders. J Alzheimer's Dis. 2008; 13(4):359-369.


161.      Seitz DP, Gruneir A, Rochon PA. Second-generation antipsychotics did not improve

       outcomes and increased costs for patients with alzheimer disease and psychosis. ACP

       J Club. 2008; 148(2):53.


162.      Seripa D, Matera MG, Franceschi M, et al. The RELN locus in alzheimer's disease. J

       Alzheimer's Dis. 2008; 14(3):335-344.




Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
                          current articles and not intended to be exhaustive.
163.      Shatenstein B, Kergoat M, Reid I. Issues in recruitment, retention, and data

       collection in a longitudinal nutrition study of community-dwelling older adults with

       early-stage alzheimer's dementia. J Appl Gerontol. 2008; 27(3):267-285.


164.      Silverberg GD, Mayo M, Saul T, Fellmann J, Carvalho J, McGuire D. Continuous CSF

       drainage in AD: Results of a double-blind, randomized, placebo-controlled study.

       Neurology. 2008; 71(3):202-209.


165.      Simonelli C, Tripodi F, Rossi R, et al. The influence of caregiver burden on sexual

       intimacy and marital satisfaction in couples with an alzheimer spouse. Int J Clin Pract.

       2008; 62(1):47-52.


166.      Skogseth R, Mulugeta E, Ballard C, et al. Neuropsychiatric correlates of

       cerebrospinal fluid biomarkers in alzheimer's disease. Dement Geriatr Cogn Disord.

       2008; 25(6):559-563.


167.      Sotiropoulos I, Cerqueira JJ, Catania C, Takashima A, Sousa N, Almeida OFX.

       Stress and glucocorticoid footprints in the brain-the path from depression to

       alzheimer's disease. Neurosci Biobehav Rev. 2008; 32(6):1161-1173.


168.      Soto ME, Nourhashemi F, Arbus C, et al. Special acute care unit for older adults

       with alzheimer's disease. Int J Geriatr Psychiatry. 2008; 23(2):215-219.


169.      Spoletini I, Marra C, Di Iulio F, et al. Facial emotion recognition deficit in amnestic

       mild cognitive impairment and alzheimer disease. American Journal of Geriatric

       Psychiatry. 2008; 16(5):389-398.


170.      Stallings TL. Association of alzheimer's disease and chlamydophila pneumoniae. J

       Infect. 2008; 56(6):423-431.


171.      Starr JM, Lonie J. Estimated pre-morbid IQ effects on cognitive and functional

       outcomes in alzheimer disease: A longitudinal study in a treated cohort. BMC

       Psychiatry. 2008; 8:27.




Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
                          current articles and not intended to be exhaustive.
172.      Steinitz M. Developing injectable immunoglobulins to treat cognitive impairment in

       alzheimer's disease. Expert Opinion on Biological Therapy. 2008; 8(5):633-642.


173.      Sultzer DL, Davis SM, Tariot PN, et al. Clinical symptom responses to atypical

       antipsychotic medications in alzheimer's disease: Phase 1 outcomes from the CATIE-

       AD effectiveness trial. Am J Psychiatry. 2008; 165(7):844-854.


174.      Supekar K, Menon V, Rubin D, Musen M, Greicius MD. Network analysis of intrinsic

       functional brain connectivity in alzheimer's disease. PLoS Computational Biology.

       2008; 4(6):e1000100.


175.      Supekar K, Menon V, Rubin D, Musen M, Greicius MD. Network analysis of intrinsic

       functional brain connectivity in alzheimer's disease. PLoS Computational Biology.

       2008; 4(6):Arte Number: e1000100. ate of Pubaton: Jun 2008.


176.      Takahashi M, Sato A, Nakajima K, et al. Poor performance in clock-drawing test

       associated with visual memory deficit and reduced bilateral hippocampal and left

       temporoparietal regional blood flows in alzheimer's disease patients. Psychiatry &

       Clinical Neurosciences. 2008; 62(2):167-173.


177.      Takata M, Nakashima M, Takehara T, et al. Detection of amyloid beta protein in

       the urine of alzheimer's disease patients and healthy individuals. Neurosci Lett. 2008;

       435(2):126-130.


178.      Tales A, Haworth J, Wilcock G, Newton P, Butler S. Visual mismatch negativity

       highlights abnormal pre-attentive visual processing in mild cognitive impairment and

       alzheimer's disease. Neuropsychologia. 2008; 46(5):1224-1232.


179.      Taylor KI, Probst A, Miserez AR, Monsch AU, Tolnay M, Medscape. Clinical course of

       neuropathologically confirmed frontal-variant alzheimer's disease. Nature Clinical

       Practice Neurology. 2008; 4(4):226-232.


180.      Teng E, Ringman JM, Ross LK, et al. Diagnosing depression in alzheimer disease

       with the national institute of mental health provisional criteria. American Journal of

       Geriatric Psychiatry. 2008; 16(6):469-477.

Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
                          current articles and not intended to be exhaustive.
181.     Thomann PA, Toro P, Dos Santos V, Essig M, Schroder J. Clock drawing

       performance and brain morphology in mild cognitive impairment and alzheimer's

       disease. Brain & Cognition. 2008; 67(1):88-93.


182.     Treiber KA, Lyketsos CG, Corcoran C, et al. Vascular factors and risk for

       neuropsychiatric symptoms in alzheimer's disease: The cache county study.

       International Psychogeriatrics. 2008; 20(3):538-553.


183.     Trouw LA, Nielsen HM, Minthon L, et al. C4b-binding protein in alzheimer's

       disease: Binding to Abeta1-42 and to dead cells. Mol Immunol. 2008; 45(13):3649-

       3660.


184.     Upadhya SC, Hegde AN. Role of the ubiquitin proteasome system in alzheimer's

       disease. BMC Biochemistry. 2007; 8(SUPPL. 1):Arte Number: S12. ate of Pubaton:

       2007.


185.     Upton N, Chuang TT, Hunter AJ, Virley DJ. 5-HT6 receptor antagonists as novel

       cognitive enhancing agents for alzheimer's disease. Neurotherapeutics. 2008;

       5(3):458-469.


186.     Urosevic N, Martins RN. Infection and alzheimer's disease: The APOE epsilon4

       connection and lipid metabolism. J Alzheimer's Dis. 2008; 13(4):421-435.


187.     Van Dijck A, Vloeberghs E, Van Dam D, Staufenbiel M, De Deyn PP. Evaluation of

       the APP23-model for alzheimer's disease in the odour paired-associate test for

       hippocampus-dependent memory. Behav Brain Res. 2008; 190(1):147-151.


188.     Viggiano MP, Galli G, Righi S, Brancati C, Gori G, Cincotta M. Visual recognition

       memory in alzheimer's disease: Repetition-lag effects. Exp Aging Res. 2008;

       34(3):267-281.


189.     Visser PJ, Verhey FRJ, Boada M, et al. Development of screening guidelines and

       clinical criteria for predementia alzheimer's disease. Neuroepidemiology. 2008;

       30(4):254-265.




Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
                          current articles and not intended to be exhaustive.
190.      Walker DG, Dalsing-Hernandez JE, Lue LF. Human postmortem brain-derived

       cerebrovascular smooth muscle cells express all genes of the classical complement

       pathway: A potential mechanism for vascular damage in cerebral amyloid angiopathy

       and alzheimer's disease. Microvasc Res. 2008; 75(3):411-419.


191.      Wang XP, Ding HL. Alzheimer's disease: Epidemiology, genetics, and beyond.

       Neuroscience Bulletin. 2008; 24(2):105-109.


192.      Weinshenker D. Functional consequences of locus coeruleus degeneration in

       alzheimer's disease. Current Alzheimer Research. 2008; 5(3):342-345.


193.      Whitehouse PJ. National institute of health and clinical excellence decision

       processes supported by UK high court: The debate about the value of alzheimer's

       disease drugs continues. J Alzheimer's Dis. 2008; 13(3):239-240.


194.      Wilks SE. Psychometric evaluation of the shortened resilience scale among

       alzheimer's caregivers. American Journal of Alzheimer's Disease & Other Dementias.

       2008; 23(2):143-149.


195.      Wisniewski T, Konietzko U. Amyloid-V immunisation for alzheimer's disease. Lancet

       Neurology. 2008; 7(9):805-811.


196.      Wolfe MS. Inhibition and modulation of gamma-secretase for alzheimer's disease.

       Neurotherapeutics. 2008; 5(3):391-398.


197.      Wu G, Sankaranarayanan S, Tugusheva K, et al. Decrease in age-adjusted

       cerebrospinal fluid beta-secretase activity in alzheimer's subjects. Clin Biochem.

       2008; 41(12):986-996.


198.      Xu W, Kawarabayashi T, Matsubara E, et al. Plasma antibodies to Abeta40 and

       Abeta42 in patients with alzheimer's disease and normal controls. Brain Res. 2008;

       1219(C):169-179.


199.      Yaari R, Kumar S, Tariot PN. Non-cholinergic drug development for alzheimer's

       disease. Expert Opinion on Drug Discovery. 2008; 3(7):745-760.



Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
                          current articles and not intended to be exhaustive.
200.      Zetterberg H, Andreasson U, Hansson O, et al. Elevated cerebrospinal fluid BACE1

       activity in incipient alzheimer disease. Archives of Neurology. 2008; 65(8):1102-

       1107.


201.      Zetterberg H. Is plasma amyloid-beta a reliable biomarker for alzheimer's disease?

       Recent Patents on Cns Drug Discovery. 2008; 3(2):109-111.


202.      Zhang L-, Wang X, Stoltenberg M, Danscher G, Huang L, Wang Z-. Abundant

       expression of zinc transporters in the amyloid plaques of alzheimer's disease brain.

       Brain Res Bull. 2008; 77(1):55-60.


203.      Zhou Y, Jia J. Effect of acupuncture given at the HT 7, ST 36, ST 40 and KI 3

       acupoints on various parts of the brains of alzheimer's disease patients. Acupunct

       Electro-Ther Res. 2008; 33(1-2):9-17.


204.      Zlokovic BV. New therapeutic targets in the neurovascular pathway in alzheimer's

       disease. Neurotherapeutics. 2008; 5(3):409-414.




Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
                          current articles and not intended to be exhaustive.
If you would like to receive additional bulletin, please tick the bulletins you would like to receive,
ensure your name and address are on the front cover and return to the library address given
overleaf.


   A&E                                                          Healthcare Associated Infection
   Allied Health Professionals                                  Healthy Heart
   Alzheimer’s disease                                          IT
   Ambulatory care                                              Lung Cancer
   Anaesthesia                                                  Medicine for the Elderly
   Asthma                                                       Multiple Sclerosis
   Burns/Dermatology/Plastics                                   Neonatal Nursing and Midwifery
   Cancer: Pain                                                 New Books
   Cancer Supportive Care                                       New Books (all sites & Nursing)
   Chaplain                                                     New Nurse
   Child Protection                                             Nutrition
   Clinical Governance                                          Orthopaedics
   Community Child Health                                       Paediatric Anaesthesia & Pain
   Community Nursing                                            Paediatric Oncology Nursing
   Complaints                                                   Paediatric Physiotherapy
   Coronary Intensive and High Dependency Care                  Paediatric Respiratory Medicine
   Corporate Services                                           Parkinson’s disease
   Day surgery                                                  Pharmacy
   Dental Care Professionals                                    Prevention & Treatment of Alcohol &
                                                             Drug Abuse (Nursing)
   Dentistry                                                    Primary Care Mental Health
   Digestive Diseases                                           Rheumatology
   Elderly Care Bulletin (Nursing)                              Sarcoma
   Epilepsy                                                     School nurses
   Guidelines                                                   Speech and Language Therapy
   Gynaecologic Oncology                                        Spinal Injuries
   Head Injury                                                  Stroke (North Glasgow)
   Health Promotion                                             Stroke (South Glasgow)
                                                                Training, education and Management
                                                             (Nursing)




                            How to Access Electronic Articles

Many of the articles in this bulletin will be available online at the NHS Scotland eLibrary

    1.   Go to the NHS Scotland eLibrary http://www.elib.scot.nhs.uk
    2.   Click on Journals
    3.   Type in the journal title and click search.
    4.   Click on the appropriate title, then select the supplier you wish to use.
    5.   Put in your Athens password at the “Athens login” link.
    6.   Select the correct year, volume, issue and page number for the article you
         want.

Please note, the articles you are accessing may be protected by copyright legislation, please
contact your librarian for a copyright declaration form if you are in any doubt. Or, consult the
Copyright Licensing Agency at http://www.cla.co.uk


If you have any questions regarding this or any other library services please contact
your librarian.

Compiled by C. Boulnois
Library Services Manager
NHS Greater Glasgow & Clyde Library Network
Central Library
Southern General Hospital
1345 Govan Rd
Glasgow
G51 4TF
0141 201 2163


 Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
                           current articles and not intended to be exhaustive.
charlotte.boulnois@sgh.scot.nhs.uk




 Current Awareness Bulletins provided by NHS Greater Glasgow & Clyde Library Network are a selection of
                           current articles and not intended to be exhaustive.

								
To top